During the development of a homogeneous immunoassay for the antibiotic vancomycin, we observed in certain patient samples a quantitation difference between the enzyme multiplied immunoassay technique (EMIT) method and the comparison method, fluorescence polarization immunoassay (FPIA). This prompted us to evaluate the integrity of vancomycin in samples from renally impaired patients. Since it has been reported in the scientific literature that vancomycin degrades into an antibiotically inactive crystalline degradation product (CDP-1) in vitro, we developed high-performance liquid chromatography (HPLC) and liquid chromatography/mass spectrometry (LC/MS) methods to determine whether CDP-1 is present in patient sera. HPLC and LC/MS analysis on samples from renally impaired patients positively identified CDP-1 in fresh samples. Next, we tested the cross-reactivity of three currently available vancomycin immunoassays, radioimmunoassay (RIA) FPIA, and EMIT, to CDP-1 prepared in our laboratory. Our data suggest that CDP-1 is recognized by FPIA and RIA, both polyclonal antibody-based methods, but not by EMIT, which uses a monoclonal antibody.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation of aortic stent endoleaks in the renally impaired patient with ferumoxytol-enhanced MR angiography.
Clin Imaging
December 2024
Department of Radiological Sciences, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address:
Purpose: To evaluate ferumoxytol-enhanced magnetic resonance angiography (FE-MRA) for assessment of endoleaks in patients with abdominal aortic aneurysms (AAA) and chronic kidney disease (CKD) status post endovascular aneurysm repair (EVAR).
Methods: Of 1854 patients who underwent FE-MRA at a single institution between 03/21/2014 and 08/21/2023, 21 patients with a history of AAA and CKD status post EVAR were retrospectively identified (IRB #13-001341). Multiplanar pre- and post-contrast HASTE, T1-VIBE, and high-resolution breath-held 3D MRA sequences were obtained, where a dose of 4 mg/kg of Ferumoxytol was infused over six minutes.
Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment.
PLoS One
December 2024
Amicus Therapeutics, Inc., Princeton, New Jersey, United States of America.
Article Synopsis
- Fabry disease is an X-linked lysosomal disorder causing complications like kidney issues and challenges with drug elimination, prompting the need to study migalastat in patients with end-stage renal disease (ESRD) on dialysis.
- This study tested a 123 mg dose of migalastat in ESRD patients compared to controls with normal kidney function, examining its pharmacokinetics, how well it's cleared during dialysis, and its tolerability.
- Results showed that migalastat is largely removed by dialysis and suggested dosing regimens for ESRD patients that could maintain effective drug levels while minimizing accumulation in tissues.
A Real-World, Prospective, Observational Study of Rivaroxaban on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-Valvular Atrial Fibrillation: XARENAL.
Korean Circ J
October 2024
Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Background And Objectives: Several real-world studies have been done in patients with nonvalvular atrial fibrillation (NVAF); however, information on its safety profile in patients with renal impairment is limited. XARENAL, a real-world study, aimed to prospectively investigate the safety profile of rivaroxaban in patients with NVAF with renal impairment (creatinine clearance [CrCl], 15-49 mL/min).
Methods: XARENAL is an observational single-arm cohort study in renal impairment NVAF patients.
Renal Impairment and Dose Adjustment of Long-Acting Injectable Antipsychotics: Are We Getting It Right? A Case Report.
Focus (Am Psychiatr Publ)
October 2024
Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
is defined as an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m with or without kidney damage. Creatinine, which is found in serum and urine, is a common biomarker to estimate renal function and is used in most eGFR equations.
View Article and Find Full Text PDFComparative Effectiveness of Albumin vs No Albumin on Renal Replacement Therapy and Mortality in Patients With Septic Shock and Renal Impairment.
Chest
October 2024
Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ.
Article Synopsis
- Albumin infusions may either protect or harm patients with septic shock and kidney issues, influencing their need for kidney replacement therapy and survival rates during their hospital stay.
- A study analyzed nearly 10,000 patients with septic shock and kidney impairment, comparing outcomes for those who received albumin within 24 hours of admission versus those who didn't.
- Results showed that the use of albumin was linked to a higher risk of requiring kidney replacement therapy or in-hospital death, especially with the use of 25% hyperoncotic albumin compared to iso-oncotic albumin.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!